EnteroBiotix Limited (“EBX”), a clinical stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced the initiation of a multi-centre randomised double-blind placebo controlled Phase 2 clinical trial. The trial has been designed to evaluate EBX-102, the .
Photo: Imperial College London website. Imperial is partnering with biotechnology company EnteroBiotix on research into the potential of therapies based on the gut bacterial community.
/PRNewswire/ EnteroBiotix Limited ("EBX"), a premier, full-spectrum microbiome therapeutics company, today announced a partnership with Imperial College.
/PRNewswire/ EnteroBiotix Limited, the premier full-spectrum microbiome therapeutics company, today announced that it has been granted a Manufacturer s.
EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeutics biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.